Gut mucosal DAMPs in IBD: From mechanisms to therapeutic implications

Mucosal Immunology

Volumn 9, Issue 3, 2016, Pages 567-582

  Boyapati, R K ^a,b   Rossi, A G ^a   Satsangi, J ^b   Ho, G T ^a,b  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL FACTOR; CALGRANULIN A; CALGRANULIN B; DAMAGE ASSOCIATED MOLECULAR PATTERN; HIGH MOBILITY GROUP B1 PROTEIN; INFLAMMASOME; INTERLEUKIN 1ALPHA; INTERLEUKIN 33; PATTERN RECOGNITION RECEPTOR; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; CALGRANULIN;

ADAPTIVE IMMUNITY; AUTOIMMUNITY; CELL DEATH; CHRONIC INFLAMMATION; CROHN DISEASE; CYTOKINE RELEASE; ENTEROPATHY; HUMAN; IMMUNOMODULATION; INFLAMMATORY BOWEL DISEASE; INNATE IMMUNITY; INTESTINE EPITHELIAL DYSFUNCTION; INTESTINE MUCOSA; MUCOSAL IMMUNITY; NECROPTOSIS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN SECRETION; REVIEW; SIGNAL TRANSDUCTION; ULCERATIVE COLITIS; ANIMAL; IMMUNOLOGY; INFLAMMATION; INFLAMMATORY BOWEL DISEASES; METABOLISM; MOLECULARLY TARGETED THERAPY; TRANSLATIONAL RESEARCH;

ANIMALS; BIOMARKERS; HUMANS; INFLAMMATION; INFLAMMATORY BOWEL DISEASES; INTESTINAL MUCOSA; LEUKOCYTE L1 ANTIGEN COMPLEX; MOLECULAR TARGETED THERAPY; RECEPTORS, PATTERN RECOGNITION; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84964978448     PISSN: 19330219     EISSN: 19353456     Source Type: Journal    
DOI: 10.1038/mi.2016.14     Document Type: Review

References (257)

1. Molodecky, N.A. et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 142, 46-54.e42 (2012).
2. Danese, S. & Fiocchi, C. Ulcerative Colitis. N. Engl. J. Med. 365, 1713-1725 (2011).
3. Abraham, C. & Cho, J.H. Inflammatory bowel disease. N. Engl. J. Med. 361, 2066-2078 (2009).
4. Boyapati, R., Satsangi, J. & Ho, G.T. Pathogenesis of Crohn's disease. F1000Prime Rep. 7, 44 (2015).
5. Baumgart, D.C. & Sandborn, W.J. Crohn's disease. Lancet 380, 1590-1605 (2012).
6. Ordas, I., Eckmann, L., Talamini, M., Baumgart, D.C. & Sandborn, W.J. Ulcerative colitis. Lancet 380, 1606-1619 (2012).
7. Turner, D., Walsh, C.M., Steinhart, A.H. & Griffiths, A.M. Response to corticosteroids in severe ulcerative colitis: A systematic review of the literature and a meta-regression. Clin. Gastroenterol. Hepatol. 5, 103-110 (2007).
8. Peyrin-Biroulet, L., Loftus, E.V. Jr, Colombel, J.F. & Sandborn, W.J. The natural history of adult Crohn's disease in population-based cohorts. Am. J. Gastroenterol. 105, 289-297 (2010).
9. Beaugerie, L., Seksik, P., Nion-Larmurier, I., Gendre, J.P. & Cosnes, J. Predictors of Crohn's disease. Gastroenterology 130, 650-656 (2006).
10. Jostins, L. et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 491, 119-124 (2012).
11. Maloy, K.J. & Powrie, F. Intestinal homeostasis and its breakdown in inflammatory bowel disease. Nature 474, 298-306 (2011).
12. Wlodarska, M., Kostic, A.D. & Xavier, R.J. An integrative view of microbiome-host interactions in inflammatory bowel diseases. Cell Host Microbe 17, 577-591.
13. Akira, S., Uematsu, S. & Takeuchi, O. Pathogen recognition and innate immunity. Cell 124, 783-801 (2006).
14. Matzinger, P. Tolerance, danger, and the extended family. Annu. Rev. Immunol. 12, 991-1045 (1994).
15. Matzinger, P. The danger model: A renewed sense of self. Science 296, 301-305 (2002).
16. Chen, G.Y. & Nunez, G. Sterile inflammation: sensing and reacting to damage. Nat. Rev. Immunol. 10, 826-837 (2010).
17. Bianchi, M.E. DAMPs, PAMPs and alarmins: all we need to know about danger. J. Leukoc. Biol. 81, 1-5 (2007).
18. Takeuchi, O. & Akira, S. Pattern recognition receptors and inflammation. Cell 140, 805-820 (2010).
19. Blander, J.M. & Sander, L.E. Beyond pattern recognition: five immune checkpoints for scaling the microbial threat. Nat. Rev. Immunol. 12, 215-225 (2012).
20. Xie, J. et al. Structural Basis for Pattern Recognition by the Receptor for Advanced Glycation End Products (RAGE). J. Biol. Chem. 283, 27255-27269 (2008).
21. Schmidt, A.M., Yan, S.D., Yan, S.F. & Stern, D.M. The biology of the receptor for advanced glycation end products and its ligands. Biochim. Biophys. 1498, 99-111 (2000).
22. Rock, K.L. & Kono, H. The inflammatory response to cell death. Annu. Rev. Pathol. 3, 99-126 (2008).
23. Schaefer, L. Complexity of danger: The diverse nature of damageassociated molecular patterns. J. Biol. Chem. 289, 35237-35245 (2014).
24. Martinon, F., Petrilli, V., Mayor, A., Tardivel, A. & Tschopp, J. Goutassociated uric acid crystals activate the NALP3 inflammasome. Nature 440, 237-241 (2006).
25. Kono, H. & Rock, K.L.How dying cells alert the immune system to danger. Nat. Rev. Immunol. 8, 279-289 (2008).
26. Johnson, G.B., Brunn, G.J. & Platt, J.L. Cutting edge: an endogenous pathway to systemic inflammatory response syndrome (SIRS)-like reactions through Toll-like receptor 4. J. Immunol. 172, 20-24 (2004).
27. Wang, H. et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science 285, 248-251 (1999).
28. Sappington, P.L. et al. HMGB1 B box increases the permeability of Caco-2 enterocytic monolayers and impairs intestinal barrier function in mice. Gastroenterology 123, 790-802 (2002).
29. Zhang, Q. et al. Circulating mitochondrial DAMPs cause inflammatory responses to injury. Nature 464, 104-107 (2010).
30. Sursal, T. et al. Plasma bacterial and mitochondrial DNA distinguish bacterial sepsis from sterile SIRS and quantify inflammatory tissue injury in nonhuman primates. Shock 39, 55-62 (2013).
31. Piccinini, A.M. & Midwood, K.S. DAMPening inflammation bymodulating TLR signalling. Mediators Inflamm, Article ID: 672395 2010 (2010).
32. Ehrchen, J.M., Sunderkötter, C., Foell, D., Vogl, T. & Roth, J. The endogenous Toll-like receptor 4 agonist S100A8/S100A9 (calprotectin) as innate amplifier of infection, autoimmunity, and cancer. J. Leukoc. Biol. 86, 557-566 (2009).
33. Cayrol, C. & Girard, J.-P. IL-33: an alarmin cytokine with crucial roles in innate immunity, inflammation and allergy. Cur. Opin. Immunol. 31, 31-37 (2014).
34. Harris, H.E., Andersson, U. & Pisetsky, D.S. HMGB1: A multifunctional alarmin driving autoimmune and inflammatory disease. Nat. Rev. Rheumatol. 8, 195-202 (2012).
35. Liew, F.Y., Pitman, N.I.& McInnes, I.B.Disease-associated functions of IL-33: The new kid in the IL-1 family. Nat. Rev. Immunol. 10, 103-110 (2010).
36. Rosin, D.L. & Okusa, M.D. Dangers within: DAMP responses to damage and cell death in kidney disease. J. Am. Soc. Nephrol. 22, 416-425 (2011).
37. Garlanda, C., Dinarello, C.A. & Mantovani, A. The interleukin-1 family: back to the future. Immunity 39, 1003-1018 (2013).
38. Tibble, J. et al. A simple method for assessing intestinal inflammation in Crohn's disease. Gut 47, 506-513 (2000).
39. Schoepfer, A.M., Trummler, M., Seeholzer, P., Seibold-Schmid, B. & Seibold, F. Discriminating IBD from IBS: comparison of the test performance of fecal markers, blood leukocytes, CRP, and IBD antibodies. Inflamm. Bowel Dis. 14, 32-39 (2008).
40. Henderson, P., Anderson, N.H. & Wilson, D.C. The diagnostic accuracy of fecal calprotectin during the investigation of suspected pediatric inflammatory bowel disease: A systematic review and meta-analysis. Am. J. Gastroenterol. 109, 637-645 (2014).
41. Lin, J.F. et al. Meta-analysis: fecal calprotectin for assessment of inflammatory bowel disease activity. Inflamm. Bowel Dis. 20, 1407-1415 (2014).
42. Ho, G.T. et al. Fecal calprotectin predicts the clinical course of acute severe ulcerative colitis. Am. J. Gastroenterol. 104, 673-678 (2009).
43. Meuwis, M.A. et al. Serum calprotectin as a biomarker for Crohn's disease. J. Crohns Colitis 7, e678-e683 (2013).
44. Benoit, S. et al. Elevated serum levels of calcium-binding S100 proteins A8 and A9 reflect disease activity and abnormal differentiation of keratinocytes in psoriasis. Br. J. Dermatol. 155, 62-66 (2006).
45. Pepper, R.J. et al. Leukocyte and serum S100A8/S100A9 expression reflects disease activity in ANCA-associated vasculitis and glomerulonephritis. Kidney Int. 83, 1150-1158 (2013).
46. Brun, J.G., Jonsson, R. & Haga, H.J. Measurement of plasma calprotectin as an indicator of arthritis and disease activity in patients with inflammatory rheumatic diseases. J. Rheumatol. 21, 733-738 (1994).
47. Frosch, M. et al. Myeloid-related proteins 8 and 14 are specifically secreted during interaction of phagocytes and activated endothelium and are useful markers for monitoring disease activity in pauciarticular-onset juvenile rheumatoid arthritis. Arthritis Rheum. 43, 628-637 (2000).
48. de la Rosa, G., Yang, D., Tewary, P., Varadhachary, A. & Oppenheim, J.J. Lactoferrin acts as an alarmin to promote the recruitment and activation of APCs and antigen-specific immune responses. J. Immunol. 180, 6868-6876 (2008).
49. Lewis, J.D. The utility of biomarkers in the diagnosis and therapy of inflammatory bowel disease. Gastroenterology 140, 1817-1826.e2 (2011).
50. de Jong, N.S., Leach, S.T. & Day, A.S. Fecal S100A12: A novel noninvasive marker in children with Crohn's disease. Inflamm. Bowel Dis. 12, 566-572 (2006).
51. Kaiser, T. et al. Faecal S100A12 as a non-invasive marker distinguishing inflammatory bowel disease from irritable bowel syndrome. Gut 56, 1706-1713 (2007).
52. Sidler,M.A., Leach, S.T. & Day, A.S. Fecal S100A12 and fecal calprotectin as noninvasive markers for inflammatory bowel disease in children. Inflamm. Bowel Dis. 14, 359-366 (2008).
53. Dabritz, J. et al. Improving relapse prediction in inflammatory bowel disease by neutrophil-derived S100A12. Inflamm. Bowel Dis. 19, 1130-1138 (2013).
54. Foell, D. et al. Neutrophil derived human S100A12 (EN-RAGE) is strongly expressed during chronic active inflammatory bowel disease. Gut 52, 847-853 (2003).
55. Leach, S.T. et al. Serum and mucosal S100 proteins, calprotectin (S100A8/S100A9) and S100A12, are elevated at diagnosis in children with inflammatory bowel disease. Scand. J. Gastroenterol. 42, 1321-1331 (2007).
56. Manolakis, A.C. et al. Moderate performance of serum S100A12, in distinguishing inflammatory bowel disease from irritable bowel syndrome. BMC Gastroenterol. 10, 118 (2010).
57. Vitali, R. et al. Fecal HMGB1 is a novel marker of intestinal mucosal inflammation in pediatric inflammatory bowel disease. Am. J. Gastroenterol. 106, 2029-2040 (2011).
58. Palone, F. et al. Role of HMGB1 as a suitable biomarker of subclinical intestinal inflammation andmucosal healing in patients with inflammatory bowel disease. Inflamm. Bowel Dis. 20, 1448-1457 (2014).
59. Beltran, C.J. et al. Characterization of the novel ST2/IL-33 system in patients with inflammatory bowel disease. Inflamm. Bowel Dis. 16, 1097-1107 (2010).
60. Pastorelli, L. et al. Epithelial-derived IL-33 and its receptor ST2 are dysregulated in ulcerative colitis and in experimental Th1/Th2 driven enteritis. Proc. Natl. Acad. Sci. USA 107, 8017-8022 (2010).
61. Kobori, A. et al. Interleukin-33 expression is specifically enhanced in inflamed mucosa of ulcerative colitis. J. Gastroenterol. 45, 999-1007 (2010).
62. Seidelin, J.B. et al. IL-33 is upregulated in colonocytes of ulcerative colitis. Immunol. Lett. 128, 80-85 (2010).
63. Sponheim, J. et al. Inflammatory bowel disease-associated interleukin-33 is preferentially expressed in ulceration-associated myofibroblasts. Am. J. Pathol. 177, 2804-2815 (2010).
64. Wakahara, K. et al. Human basophils interact with memory T cells to augment Th17 responses. Blood 120, 4761-4771 (2012).
65. Ludwiczek, O. et al. Imbalance between interleukin-1 agonists and antagonists: relationship to severity of inflammatory bowel disease. Clin. Exp. Immunol. 138, 323-329 (2004).
66. Youngman, K.R. et al. Localization of intestinal interleukin 1 activity and protein and gene expression to lamina propria cells. Gastroenterology 104, 749-758 (1993).
67. Nenci, A. et al. Epithelial NEMO links innate immunity to chronic intestinal inflammation. Nature 446, 557-561 (2007).
68. Lotze, M.T. & Tracey, K.J. High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat. Rev. Immunol. 5, 331-342 (2005).
69. Park, J.S. et al. Involvement of toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. J. Biol. Chem. 279, 7370-7377 (2004).
70. Yu, M. et al. HMGB1 signals through toll-like receptor (TLR) 4 and TLR2. Shock 26, 174-179 (2006).
71. Tian, J. et al. Toll-like receptor 9-dependent activation by DNA-containing immune complexes ismediated by HMGB1 and RAGE. Nat. Immunol. 8, 487-496 (2007).
72. Dumitriu, I.E. et al. Release of high mobility group box 1 by dendritic cells controls T cell activation via the receptor for advanced glycation end products. J. Immunol. 174, 7506-7515 (2005).
73. Li, G., Tang, D. & Lotze, M.T. Mé nage à Trois in stress: DAMPs, redox and autophagy. Semin. Cancer Biol. 23, 380-390 (2013).
74. Andersson, U., Erlandsson-Harris, H., Yang, H. & Tracey, K.J. HMGB1 as a DNA-binding cytokine. J. Leukoc. Biol. 72, 1084-1091 (2002).
75. Qin, S. et al. Role of HMGB1 in apoptosis-mediated sepsis lethality. J. Exp. Med. 203, 1637-1642 (2006).
76. Dave, S.H. et al. Ethyl pyruvate decreases HMGB1 release and ameliorates murine colitis. J. Leukoc. Biol. 86, 633-643 (2009).
77. Vitali, R. et al. Dipotassium glycyrrhizate inhibits HMGB1-dependent inflammation and ameliorates colitis in mice. PLoS One 8, e66527 (2013).
78. Maeda, S. et al. Essential roles of high-mobility group box 1 in the development of murine colitis and colitis-associated cancer. Biochem. Biophys. Res. Commun. 360, 394-400 (2007).
79. Calogero, S. et al. The lack of chromosomal protein Hmg1 does not disrupt cell growth but causes lethal hypoglycaemia in newborn mice. Nat. Genet. 22, 276-280 (1999).
80. Zhu, X. et al. Cytosolic HMGB1 controls the cellular autophagy/apoptosis checkpoint during inflammation. J. Clin. Invest. 125, 1098-1110 (2015).
81. Huebener, P. et al. The HMGB1/RAGE axis triggers neutrophil-mediated injury amplification following necrosis. J. Clin. Invest. 125, 539-550 (2015).
82. Huang, H. et al. Hepatocyte-specific high-mobility group box 1 deletion worsens the injury in liver ischemia/reperfusion: A role for intracellular highmobility group box 1 in cellular protection. Hepatology 59, 1984-1997 (2014).
83. Kang, R. et al. Intracellular Hmgb1 inhibits inflammatory nucleosome release and limits acute pancreatitis in mice. Gastroenterology 146, 1097-1107 (2014).
84. Yanai, H. et al. Conditional ablation of HMGB1 in mice reveals its protective function against endotoxemia and bacterial infection. Proc. Natl. Acad. Sci. USA 110, 20699-20704 (2013).
85. Foell, D., Wittkowski, H., Vogl, T. & Roth, J. S100 proteins expressed in phagocytes: A novel group of damage-associated molecular pattern molecules. J. Leukoc. Biol. 81, 28-37 (2007).
86. Robinson, M.J., Tessier, P., Poulsom, R. & Hogg, N. The S100 family heterodimer, MRP-8/14, binds with high affinity to heparin and heparan sulfate glycosaminoglycans on endothelial cells. J. Biol. Chem. 277, 3658-3665 (2001).
87. Vogl, T. et al. Mrp8 and Mrp14 are endogenous activators of Toll-like receptor 4, promoting lethal, endotoxin-induced shock. Nat. Med. 13, 1042-1049 (2007).
88. Srikrishna, G. et al. Two proteinsmodulating transendothelialmigration of leukocytes recognize novel carboxylated glycans on endothelial cells. J. Immunol. 166, 4678-4688 (2001).
89. Frosch, M. et al. Expression of MRP8 and MRP14 by macrophages is a marker for severe forms of glomerulonephritis. J. Leukoc. Biol. 75, 198-206 (2004).
90. Steinbakk, M. et al. Antimicrobial actions of calcium binding leucocyte L1 protein, calprotectin. Lancet 336, 763-765 (1990).
91. Liu, J.Z. et al. Zinc sequestration by the neutrophil protein calprotectin enhances Salmonella growth in the inflamed gut. Cell Host Microbe 11, 227-239 (2012).
92. Miles, K. et al. Dying and necrotic neutrophils are anti-inflammatory secondary to the release of alpha-defensins. J. Immunol. 183, 2122-2132 (2009).
93. Urban, C.F. et al. Neutrophil extracellular traps contain calprotectin, a cytosolic protein complex involved in host defense against Candida albicans. PLoS Pathog. 5, e1000639 (2009).
94. Rider, P., Carmi, Y., Voronov, E. & Apte, R.N. Interleukin-1a. Semin. Immunol. 25, 430-438 (2013).
95. Moussion, C., Ortega, N. & Girard, J.-P. The IL-1-like cytokine IL-33 is constitutively expressed in the nucleus of endothelial cells and epithelial cells in vivo: A novel 'alarmin'?. PLoS One 3, e3331 (2008).
96. Carta, S., Lavieri, R. & Rubartelli, A. Different members of the IL-1 family come out in different ways: DAMPs vs cytokines? Front. Immunol. 4, 123 (2013).
97. Lamkanfi, M. & Dixit, V.M. IL-33 raises alarm. Immunity 31, 5-7 (2009).
98. Lüthi, A.U. et al. Suppression of interleukin-33 bioactivity through proteolysis by apoptotic caspases. Immunity 31, 84-98 (2009).
99. Cohen, I. et al. Differential release of chromatin-bound IL-1alpha discriminates between necrotic and apoptotic cell death by the ability to induce sterile inflammation. Proc. Natl. Acad. Sci. USA 107, 2574-2579 (2010).
100. Dinarello, C.A. Immunological and inflammatory functions of the interleukin-1 family. Annu. Rev. Immunol. 27, 519-550 (2009).
101. Chun-Jen, C. et al. Identification of a key pathway required for the sterile inflammatory response triggered by dying cells. Nat. Med. 13, 851-856 (2007).
102. Rider, P. et al. IL-1alpha and IL-1beta recruit different myeloid cells and promote different stages of sterile inflammation. J. Immunol. 187, 4835-4843 (2011).
103. Oboki, K. et al. IL-33 is a crucial amplifier of innate rather than acquired immunity. Proc. Natl. Acad. Sci. USA 107, 18581-18586 (2010).
104. Salas, A. The IL-33/ST2 axis: yet another therapeutic target in inflammatory bowel disease? Gut 62, 1392-1393 (2013).
105. Nunes, T., Bernardazzi, C. & de Souza, H.S. Interleukin-33 and inflammatory bowel diseases: lessons from human studies. Mediators Inflamm. 2014, 423957 (2014).
106. Baumann, C. et al. T-bet-and STAT4-dependent IL-33 receptor expression directly promotes antiviral Th1 cell responses. Proc. Natl. Acad. Sci. USA 112, 4056-4061 (2015).
107. Latiano, A. et al. Associations between genetic polymorphisms in IL-33, IL1R1 and risk for inflammatory bowel disease. PLoS One 8, e62144 (2013).
108. Cominelli, F. et al. Interleukin 1 (IL-1) gene expression, synthesis, and effect of specific IL-1 receptor blockade in rabbit immune complex colitis. J. Clin. Invest. 86, 972-980 (1990).
109. Bersudsky, M. et al. Non-redundant properties of IL-1a and IL-1b during acute colon inflammation in mice. Gut 63, 598-609 (2014).
110. Fritz, G. RAGE: A single receptor fits multiple ligands. Trends Biochem. Sci. 36, 625-632 (2011).
111. Stern, D., Yan, S.D., Yan, S.F. & Schmidt, A.M. Receptor for advanced glycation endproducts: A multiligand receptor magnifying cell stress in diverse pathologic settings. Adv. Drug Deliv. Rev. 54, 1615-1625 (2002).
112. Ciccocioppo, R. et al. Role of the advanced glycation end products receptor in Crohn's disease inflammation. World J. Gastroenterol. 19, 8269-8281 (2013).
113. Dabritz, J. et al. The functional-374 T/A polymorphism of the receptor for advanced glycation end products maymodulate Crohn's disease. Am. J. Physiol. Gastrointest. Liver Physiol. 300, G823-G832 (2011).
114. Zen, K.,Chen,C.X., Chen, Y.T.,Wilton, R. & Liu, Y. Receptor for advanced glycation endproducts mediates neutrophil migration across intestinal epithelium. J. Immunol. 178, 2483-2490 (2007).
115. Hofmann, M.A. et al. RAGE mediates a novel proinflammatory axis: A central cell surface receptor for S100/calgranulin polypeptides. Cell 97, 889-901 (1999).
116. Malickova, K. et al. Anti-inflammatory effect of biological treatment in patients with inflammatory bowel diseases: calprotectin and IL-6 changes do not correspond to sRAGE changes. Scand. J. Clin. Lab. Invest. 70, 294-299 (2010).
117. Yilmaz, Y., Yonal, O., Eren, F., Atug, O. & Over Hamzaoglu, H. Serum levels of soluble receptor for advanced glycation endproducts (sRAGE) are higher in ulcerative colitis and correlate with disease activity. J. Crohns Colitis 5, 402-406 (2011).
118. Ciccocioppo, R. et al. The circulating level of soluble receptor for advanced glycation end products displays different patterns in ulcerative colitis and Crohn's disease: A cross-sectional study. Dig. Dis. Sci. 60, 2327-2337 (2015).
119. Meijer, B. et al. Total soluble and endogenous secretory receptor for advanced glycation endproducts (RAGE) in IBD. J. Crohns Colitis 8, 513-520 (2014).
120. El Mezayen, R. et al. Endogenous signals released from necrotic cells augment inflammatory responses to bacterial endotoxin. Immunol. Lett. 111, 36-44 (2007).
121. Saurer, L. et al. Elevated levels of serum-soluble triggering receptor expressed on myeloid cells-1 in patients with IBD do not correlate with intestinal TREM-1 mRNA expression and endoscopic disease activity. J. Crohns Colitis 6, 913-923 (2012).
122. Schenk, M., Bouchon, A., Seibold, F. & Mueller, C. TREM-1-expressing intestinal macrophages crucially amplify chronic inflammation in experimental colitis and inflammatory bowel diseases. J. Clin. Invest. 117, 3097-3106 (2007).
123. Chen, G.Y., Tang, J., Zheng, P. & Liu, Y. CD24 and Siglec-10 selectively repress tissue damage-induced immune responses. Science 323, 1722-1725 (2009).
124. Liu, Y., Chen, G.Y. & Zheng, P. CD24-Siglec G/10 discriminates dangerfrom pathogen-associated molecular patterns. Trends Immunol. 30, 557-561 (2009).
125. Chen, G.Y. et al. Amelioration of sepsis by inhibiting sialidase-mediated disruption of the CD24-SiglecG interaction. Nat.Biotechnol. 29, 428-435 (2011).
126. Shi, Y. & Rock, K.L. Cell death releases endogenous adjuvants that selectively enhance immune surveillance of particulate antigens. Eur. J. Immunol. 32, 155-162 (2002).
127. Gallucci, S., Lolkema, M. & Matzinger, P. Natural adjuvants: endogenous activators of dendritic cells. Nat. Med. 5, 1249-1255 (1999).
128. Shi, Y., Zheng,W. & Rock, K.L. Cell injury releases endogenous adjuvants that stimulate cytotoxic T cell responses. Proc. Natl. Acad. Sci. USA 97, 14590-14595 (2000).
129. Rovere-Querini, P. et al. HMGB1 is an endogenous immune adjuvant released by necrotic cells. EMBO Rep. 5, 825-830 (2004).
130. Yang, D. et al. High mobility group box-1 protein induces the migration and activation of human dendritic cells and acts as an alarmin. J. Leukoc. Biol. 81, 59-66 (2007).
131. Dumitriu, I.E., Bianchi,M.E., Bacci, M.,Manfredi, A.A. & Rovere-Querini, P. The secretion ofHMGB1is required for themigration ofmaturing dendritic cells. J. Leukoc. Biol. 81, 84-91 (2007).
132. Flohe, S.B. et al. Human heat shock protein 60 induces maturation of dendritic cells versus a Th1-promoting phenotype. J. Immunol. 170, 2340-2348 (2003).
133. Somersan, S. et al. Primary tumor tissue lysates are enriched in heat shock proteins and induce the maturation of human dendritic cells. J. Immunol. 167, 4844-4852 (2001).
134. Chen, T., Guo, J., Han, C., Yang, M. & Cao, X. Heat shock protein 70, released from heat-stressed tumor cells, initiates antitumor immunity by inducing tumor cell chemokine production and activating dendritic cells via TLR4 pathway. J. Immunol. 182, 1449-1459 (2009).
135. Ishii, K.J. et al. Genomic DNA released by dying cells induces the maturation of APCs. J. Immunol. 167, 2602-2607 (2001).
136. Shi, Y., Evans, J.E. & Rock, K.L. Molecular identification of a danger signal that alerts the immune system to dying cells. Nature 425, 516-521 (2003).
137. Messmer, D. et al. High mobility group box protein 1: an endogenous signal for dendritic cell maturation and Th1 polarization. J. Immunol. 173, 307-313 (2004).
138. Shi, Y., Galusha, S.A. & Rock, K.L. Cutting edge: elimination of an endogenous adjuvant reduces the activation of CD8 T lymphocytes to transplanted cells and in an autoimmune diabetes model. J. Immunol. 176, 3905-3908 (2006).
139. Scheibner, K.A. et al. Hyaluronan fragments act as an endogenous danger signal by engaging TLR2. J. Immunol. 177, 1272-1281 (2006).
140. Hwang, S.A., Kruzel, M.L. & Actor, J.K. Lactoferrin augments BCG vaccine efficacy to generate T helper response and subsequent protection against challenge with virulent Mycobacterium tuberculosis. Int. Immunopharmacol. 5, 591-599 (2005).
141. Kenji, T. et al. Defensins act as potent adjuvants that promote cellular and humoral immune responses in mice to a lymphoma idiotype and carrier antigens. Int. Immunol. 12, 691-700 (2000).
142. Garg, A.D., Martin, S., Golab, J. & Agostinis, P. Danger signalling during cancer cell death: origins, plasticity and regulation. Cell Death Differ. 21, 26-38 (2014).
143. Loser, K. et al. The Toll-like receptor 4 ligandsMrp8 and Mrp14 are crucial in the development of autoreactive CD8+ Tcells. Nat. Med. 16, 713-717 (2010).
144. Petersen, B. et al. The alarmin Mrp8/14 as regulator of the adaptive immune response during allergic contact dermatitis. EMBO J. 32, 100-111 (2013).
145. Schiering, C. et al. The alarmin IL-33 promotes regulatory T-cell function in the intestine. Nature 513, 564-568 (2014).
146. Grob, P., Doser, K., Falk, W., Obermeier, F. & Hofmann, C. IL-33 attenuates development and perpetuation of chronic intestinal inflammation. Inflamm. Bowel Dis. 18, 1900-1909 (2012).
147. Salim, S.Y. & Soderholm, J.D. Importance of disrupted intestinal barrier in inflammatory bowel diseases. Inflamm. Bowel Dis. 17, 362-381 (2011).
148. Marchiando, A.M., Graham, W.V. & Turner, J.R. Epithelial barriers in homeostasis and disease. Annu. Rev. Pathol. 5, 119-144 (2010).
149. Sedhom, M.A.K. et al. Neutralisation of the interleukin-33/ST2 pathway ameliorates experimental colitis through enhancement of mucosal healing in mice. Gut 62, 1714-1723 (2012).
150. Yang, R. et al. Anti-HMGB1 neutralizing antibody ameliorates gut barrier dysfunction and improves survival after hemorrhagic shock. Mol. Med. 12, 105-114 (2006).
151. Wang, L., Luo, H., Chen, X., Jiang, Y. & Huang, Q. Functional characterization of S100A8 and S100A9 in altering monolayer permeability of human umbilical endothelial cells. PLoS One 9, e90472 (2014).
152. Liu, S. et al. HMGB1 is secreted by immunostimulated enterocytes and contributes to cytomix-induced hyperpermeability of Caco-2 monolayers. Am. J. Physiol. Cell Physiol. 290, C990-C999 (2006).
153. Foell, D. et al. Phagocyte-specific S100 proteins are released from affected mucosa and promote immune responses during inflammatory bowel disease. J. Pathol. 216, 183-192 (2008).
154. Viemann,D. et al. MRP8/MRP14 impairs endothelial integrity and induces a caspase-dependent and-independent cell death program. Blood 109, 2453-2460 (2007).
155. Nakahira, K. et al. Autophagy proteins regulate innate immune responses by inhibiting the release of mitochondrial DNA mediated by the NALP3 inflammasome. Nat. Immunol. 12, 222-230 (2011).
156. Siegmund, B. Interleukin-18 in intestinal inflammation: friend and foe? Immunity 32, 300-302 (2010).
157. Zaki, M.H. et al. The NLRP3 inflammasome protects against loss of epithelial integrity and mortality during experimental colitis. Immunity 32, 379-391 (2010).
158. Bauer, C. et al. Colitis induced in mice with dextran sulfate sodium (DSS) is mediated by the NLRP3 inflammasome. Gut 59, 1192-1199 (2010).
159. Allen, I.C. et al. The NLRP3 inflammasome functions as a negative regulator of tumorigenesis during colitis-associated cancer. J. Exp. Med. 207, 1045-1056 (2010).
160. Wlodarska, M. et al. NLRP6 inflammasome orchestrates the colonic hostmicrobial interface by regulating goblet cell mucus secretion. Cell 156, 1045-1059 (2014).
161. Elinav, E. et al. NLRP6 inflammasome regulates colonic microbial ecology and risk for colitis. Cell 145, 745-757 (2011).
162. Günther, C., Neumann, H., Neurath, M.F. & Becker, C. Apoptosis, necrosis and necroptosis: cell death regulation in the intestinal epithelium. Gut 62, 1062-1071 (2013).
163. Kaczmarek, A., Vandenabeele, P. & Krysko, D.V. Necroptosis: The release of damage-associated molecular patterns and its physiological relevance. Immunity 38, 209-223 (2013).
164. Welz, P.S. et al. FADDprevents RIP3-mediated epithelial cell necrosis and chronic intestinal inflammation. Nature 477, 330-334 (2011).
165. Gunther, C. et al. Caspase-8 regulates TNF-alpha-induced epithelial necroptosis and terminal ileitis. Nature 477, 335-339 (2011).
166. Pasparakis, M. & Vandenabeele, P. Necroptosis and its role in inflammation. Nature 517, 311-320 (2015).
167. Linkermann, A. & Green, D.R. Necroptosis. N. Engl. J. Med. 370, 455-465 (2014).
168. Vandenabeele, P., Galluzzi, L., Vanden Berghe, T. & Kroemer, G. Molecular mechanisms of necroptosis: an ordered cellular explosion. Nat. Rev. Mol. Cell Biol. 11, 700-714 (2010).
169. Sun, L. et al. Mixed lineage kinase domain-like protein mediates necrosis signaling downstream of RIP3 kinase. Cell 148, 213-227 (2012).
170. Takahashi, N. et al. RIPK1 ensures intestinal homeostasis by protecting the epithelium against apoptosis. Nature 513, 95-99 (2014).
171. Dannappel, M. et al. RIPK1 maintains epithelial homeostasis by inhibiting apoptosis and necroptosis. Nature 513, 90-94 (2014).
172. Degterev, A. et al. Identification of RIP1 kinase as a specific cellular target of necrostatins. Nat. Chem. Biol. 4, 313-321 (2008).
173. Weinlich, R. et al. Protective roles for caspase-8 and cFLIP in adult homeostasis. Cell Rep. 5, 340-348 (2013).
174. Pierdomenico,M. et al. Necroptosis is active in childrenwith inflammatory bowel disease and contributes to heighten intestinal inflammation. Am. J. Gastroenterol. 109, 279-287 (2014).
175. Martin, S.J., Henry, C.M. & Cullen, S.P. A perspective on mammalian caspases as positive and negative regulators of inflammation. Mol. Cell 46, 387-397 (2012).
176. Taylor, R.C.,Cullen, S.P. & Martin, S.J. Apoptosis: controlled demolition at the cellular level. Nat. Rev. Mol. Cell Biol. 9, 231-241 (2008).
177. Choi, S.H. et al. Lipoprotein accumulation in macrophages via toll-like receptor-4-dependent fluid phase uptake. Circ. Res. 104, 1355-1363 (2009).
178. Imai, Y. et al. Identification of oxidative stress and Toll-like receptor 4 signaling as a key pathway of acute lung injury. Cell 133, 235-249 (2008).
179. Rouhiainen, A., Tumova, S., Valmu, L., Kalkkinen, N. & Rauvala, H. Pivotal advance: analysis of proinflammatory activity of highly purified eukaryotic recombinant HMGB1 (amphoterin). J. Leukoc. Biol. 81, 49-58 (2007).
180. Kang,R., Tang,D., Lotze, M.T.& Zeh,H.J. 3rdRAGEregulates autophagy and apoptosis following oxidative injury. Autophagy 7, 442-444 (2011).
181. Tang, D. et al. HMGB1 release and redox regulates autophagy and apoptosis in cancer cells. Oncogene 29, 5299-5310 (2010).
182. Kazama, H. et al. Induction of immunological tolerance by apoptotic cells requires caspase-dependent oxidation of high-mobility group box-1 protein. Immunity 29, 21-32 (2008).
183. Venereau, E. et al. Mutually exclusive redox forms ofHMGB1promote cell recruitment or proinflammatory cytokine release. J. Exp. Med. 209, 1519-1528 (2012).
184. Shimada, K. et al. Oxidized mitochondrial DNA activates the NLRP3 inflammasome during apoptosis. Immunity 36, 401-414 (2012).
185. Pazmandi, K. et al. Oxidative modification enhances the immunostimulatory effects of extracellular mitochondrial DNA on plasmacytoid dendritic cells. Free Radic. Biol. Med. 77, 281-290 (2014).
186. Kaser, A. et al. XBP1 links ER stress to intestinal inflammation and confers genetic risk for human inflammatory bowel disease. Cell 134, 743-756 (2008).
187. Murthy, A. et al. A Crohn's disease variant in Atg16l1 enhances its degradation by caspase 3. Nature 506, 456-462 (2014).
188. Zheng, W. et al. Evaluation of AGR2 and AGR3 as candidate genes for inflammatory bowel disease. Genes Immun. 7, 11-18 (2006).
189. Zhou, R., Yazdi, A.S., Menu, P. & Tschopp, J. A role for mitochondria in NLRP3 inflammasome activation. Nature 469, 221-225 (2011).
190. Iyer, S.S. et al. Necrotic cells trigger a sterile inflammatory response through the Nlrp3 inflammasome. Proc. Natl. Acad. Sci. 106, 20388-20393 (2009).
191. Saitoh, T. et al. Loss of the autophagy protein Atg16L1 enhances endotoxin-induced IL-1beta production. Nature 456, 264-268 (2008).
192. Oka, T. et al. Mitochondrial DNA that escapes from autophagy causes inflammation and heart failure. Nature 485, 251-255 (2012).
193. Cadwell, K. et al. A key role for autophagy and the autophagy gene Atg16l1 in mouse and human intestinal Paneth cells. Nature 456, 259-263 (2008).
194. Lassen, K.G. et al. Atg16L1 T300A variant decreases selective autophagy resulting in altered cytokine signaling and decreased antibacterial defense. Proc. Natl. Acad. Sci. USA 111, 7741-7746 (2014).
195. Adolph, T.E. et al. Paneth cells as a site of origin for intestinal inflammation. Nature 503, 272-276 (2013).
196. Conway, K.L. et al. Atg16l1 is required for autophagy in intestinal epithelial cells and protection of mice from Salmonella infection. Gastroenterology 145, 1347-1357 (2013).
197. Luo, Y., Li, S.J., Yang, J., Qiu, Y.Z. & Chen, F.P. HMGB1 induces an inflammatory response in endothelial cells via the RAGE-dependent endoplasmic reticulum stress pathway. Biochem. Biophys. Res. Commun. 438, 732-738 (2013).
198. Zhu, X.M. et al. Endoplasmic reticulum stress and its regulator XBP-1 contributes to dendritic cell maturation and activation induced by high mobility group box-1 protein. Int. J. Biochem. Cell Biol. 44, 1097-1105 (2012).
199. Garg, A.D. et al. A novel pathway combining calreticulin exposure and ATP secretion in immunogenic cancer cell death. EMBO J. 31, 1062-1079 (2012).
200. Wang, Y. et al. Necroptosis inhibitor necrostatin-1 promotes cell protection and physiological function in traumatic spinal cord injury. Neuroscience 266, 91-101 (2014).
201. Zhou, Y. et al. Protective effects of necrostatin-1 against concanavalin A-induced acute hepatic injury in mice. Mediators Inflamm. 2013, 706156-706156 (2013).
202. Zhang, A. et al. Necrostatin-1 inhibits Hmgb1-IL-23/IL-17 pathway and attenuates cardiac ischemia reperfusion injury. Transpl. Int. 27, 1077-1085 (2014).
203. Remijsen, Q. et al. Depletion of RIPK3 or MLKL blocks TNF-driven necroptosis and switches towards a delayed RIPK1 kinase-dependent apoptosis. Cell Death Dis. 5, e1004 (2014).
204. Rubinsztein, D.C., Gestwicki, J.E.,Murphy, L.O. & Klionsky,D.J. Potential therapeutic applications of autophagy. Nat. Rev. Drug Discov. 6, 304-312 (2007).
205. Yin, H. et al. Sirolimus ameliorates inflammatory responses by switching the regulatory T/T helper type 17 profile in murine colitis. Immunology 139, 494-502 (2013).
206. Matsuda, C. et al. Therapeutic effect of a new immunosuppressive agent, everolimus, on interleukin-10 gene-deficient mice with colitis. Clin. Exp. Immunol. 148, 348-359 (2007).
207. Massey, D.C., Bredin, F. & Parkes, M. Use of sirolimus (rapamycin) to treat refractory Crohn's disease. Gut 57, 1294-1296 (2008).
208. Reinisch, W. et al. A multicenter, randomized, double-blind trial of everolimus versus azathioprine and placebo to maintain steroid-induced remission in patients with moderate-to-severe active Crohn's disease. Am. J. Gastroenterol. 103, 2284-2292 (2008).
209. Palmer, G. et al. Inhibition of interleukin-33 signaling attenuates the severity of experimental arthritis. Arthritis Rheum. 60, 738-749 (2009).
210. Sunahori, K. et al. Increased expression of receptor for advanced glycation end products by synovial tissue macrophages in rheumatoid arthritis. Arthritis Rheum. 54, 97-104 (2006).
211. Wendt, T.M. et al. RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. Am. J. Pathol. 162, 1123-1137 (2003).
212. Kislinger, T. et al. Receptor for advanced glycation end products mediates inflammation and enhanced expression of tissue factor in vasculature of diabetic apolipoprotein E-null mice. Arterioscler. Thromb. Vasc. Biol. 21, 905-910 (2001).
213. Myint, K.M. et al. Blockade of diabetic vascular injury by controlling of AGE-RAGE system. Curr. Drug Targets 6, 447-452 (2005).
214. Lutterloh, E.C. et al. Inhibition of the RAGE products increases survival in experimental models of severe sepsis and systemic infection. Crit. Care 11, R122 (2007).
215. Kuroiwa, Y. et al. Identification and characterization of the direct interaction between methotrexate (MTX) and high-mobility group box 1 (HMGB1) protein. PLoS One 8, e63073 (2013).
216. Zhou, J. et al. TREM-1 inhibition attenuates inflammation and tumor within the colon. Int. Immunopharmacol. 17, 155-161 (2013).
217. Hobbs, J.A. et al. Myeloid cell function in MRP-14 (S100A9) null mice. Mol. Cell. Biol. 23, 2564-2576 (2003).
218. Manitz, M.P. et al. Loss of S100A9 (MRP14) results in reduced interleukin-8-induced CD11b surface expression, a polarized microfilament system, and diminished responsiveness to chemoattractants in vitro. Mol. Cell. Biol. 23, 1034-1043 (2003).
219. Bjork, P. et al. Identification of human S100A9 as a novel target for treatment of autoimmune disease via binding to quinoline-3-carboxamides. PLoS Biol. 7, e97 (2009).
220. Bengtsson, A.A. et al. Pharmacokinetics, tolerability, and preliminary efficacy of paquinimod (ABR-215757), a new quinoline-3-carboxamide derivative: studies in lupus-prone mice and a multicenter, randomized, double-blind, placebo-controlled, repeat-dose, dose-ranging study in patients with systemic lupus erythematosus. Arthritis Rheum. 64, 1579-1588 (2012).
221. Karussis, D.M. et al. Treatment of chronic-relapsing experimental autoimmune encephalomyelitis with the synthetic immunomodulator linomide (quinoline-3-carboxamide). Proc. Natl. Acad. Sci. USA 90, 6400-6404 (1993).
222. Brunmark, C. et al. The new orally active immunoregulator laquinimod (ABR-215062) effectively inhibits development and relapses of experimental autoimmune encephalomyelitis. J. Neuroimmunol. 130, 163-172 (2002).
223. Bjork, J. & Kleinau, S. Paradoxical effects of LS-2616 (Linomide) treatment in the type II collagen arthritis model in mice. Agents Actions 27, 319-321 (1989).
224. Coutant, R. et al. Low dose linomide in Type I juvenile diabetes of recent onset: A randomised placebo-controlled double blind trial. Diabetologia 41, 1040-1046 (1998).
225. Polman, C. et al. Treatment with laquinimod reduces development of active MRI lesions in relapsing MS. Neurology 64, 987-991 (2005).
226. Maiseyeu, A. et al. In vivo targeting of inflammation-associated myeloidrelated protein 8/14 via gadolinium immunonanoparticles. Arterioscler. Thromb. Vasc. Biol. 32, 962-970 (2012).
227. Spychalowicz, A., Wilk, G., Ś liwa, T., Ludew, D. & Guzik, T.J. Novel therapeutic approaches in limiting oxidative stress and inflammation. Curr. Pharm. Biotechnol. 13, 2456-2466 (2012).
228. Ozcan, U. et al. Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science 306, 457-461 (2004).
229. Ozcan, U. et al. Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes. Science 313, 1137-1140 (2006).
230. Uchida, A., Yamada, T., Hayakawa, T. & Hoshino, M. Taurochenodeoxycholic acid ameliorates and ursodeoxycholic acid exacerbates small intestinal inflammation. Am. J. Physiol. 272, G1249-G1257 (1997).
231. Imaeda, H. et al. Interleukin-33 suppresses Notch ligand expression and prevents goblet cell depletion in dextran sulfate sodium-induced colitis. Int. J. Mol. Med. 28, 573-578 (2011).
232. Duan, L. et al. Interleukin-33 ameliorates experimental colitis through promoting Th2/Foxp3(+) regulatory T-cell responses in mice. Mol. Med. 18, 753-761 (2012).
233. Gross, P., Doser, K., Falk, W., Obermeier, F. & Hofmann, C. IL-33 attenuates development and perpetuation of chronic intestinal inflammation. Inflamm. Bowel Dis. 18, 1900-1909 (2012).
234. Peetermans, W.E., D'Haens, G.R., Ceuppens, J.L., Rutgeerts, P. & Geboes, K. Mucosal expression by B7-positive cells of the 60-kilodalton heat-shock protein in inflammatory bowel disease. Gastroenterology 108, 75-82 (1995).
235. Tomasello, G. et al. Hsp10, Hsp70, and Hsp90 immunohistochemical levels change in ulcerative colitis after therapy. Eur. J. Histochem. 55, e38-e38 (2011).
236. Ludwig, D. et al. Enhanced intestinal expression of heat shock protein 70 in patients with inflammatory bowel diseases. Dig. Dis. Sci. 44, 1440-1447 (1999).
237. Rodolico, V. et al. Hsp60 and Hsp10 increase in colon mucosa of Crohn's disease and ulcerative colitis. Cell Stress Chaperones 15, 877-884 (2010).
238. Hu, S. et al. Translational inhibition of colonic epithelial heat shock proteins by IFN-gamma and TNF-alpha in intestinal inflammation. Gastroenterology 133, 1893-1904 (2007).
239. Collins, C.B. et al. Targeted inhibition of heat shock protein 90 suppresses tumor necrosis factor-A and ameliorates murine intestinal inflammation. Inflamm. Bowel Dis. 20, 685-694 (2014).
240. Riedl, S. et al. Serum tenascin-C is an indicator of inflammatory bowel disease activity. Int. J. Colorectal Dis. 16, 285-291 (2001).
241. Riedl, S. et al. Mucosal tenascin C content in inflammatory and neoplastic diseases of the large bowel. Dis. Colon Rectum 41, 86-92 (1998).
242. Dueck, M. et al. Detection of tenascin-C isoforms in colorectal mucosa, ulcerative colitis, carcinomas and liver metastases. Int. J. Cancer 82, 477-483 (1999).
243. Magnusson,M.K. et al. Response to infliximab therapy in ulcerative colitis is associated with decreased monocyte activation, reduced CCL2 expression and downregulation of tenascin C. J. Crohns Colitis 9, 56-65 (2015).
244. Kessler, S. et al. Hyaluronan (HA) deposition precedes and promotes leukocyte recruitment in intestinal inflammation. Clin. Transl. Sci. 1, 57-61 (2008).
245. Zheng, Y., Humphry, M., Maguire, J.J., Bennett, M.R. & Clarke, M.C. Intracellular interleukin-1 receptor 2 binding prevents cleavage and activity of interleukin-1alpha, controlling necrosis-induced sterile inflammation. Immunity 38, 285-295 (2013).
246. Jensen-Jarolim, E. et al. The constitutive expression of galectin-3 is downregulated in the intestinal epithelia of Crohn's disease patients, and tumour necrosis factor alpha decreases the level of galectin-3-specific mRNAin HCT-8 cells. Eur. J. Gastroenterol. Hepatol. 14, 145-152 (2002).
247. Muller, S. et al. Galectin-3 modulates T cell activity and is reduced in the inflamed intestinal epithelium in IBD. Inflamm. Bowel Dis. 12, 588-597 (2006).
248. Frol'ova, L. et al. Detection of galectin-3 in patients with inflammatory bowel diseases: new serum marker of active forms of IBD?. Inflamm. Res. 58, 503-512 (2009).
249. Santucci, L. et al. Galectin-1 suppresses experimental colitis in mice. Gastroenterology 124, 1381-1394 (2003).
250. Paclik, D. et al. Galectin-2 induces apoptosis of lamina propria T lymphocytes and ameliorates acute and chronic experimental colitis in mice. J. Mol. Med. (Berl) 86, 1395-1406 (2008).
251. Hokama, A. et al. Induced reactivity of intestinal CD4(+) T cells with an epithelial cell lectin, galectin-4, contributes to exacerbation of intestinal inflammation. Immunity 20, 681-693 (2004).
252. Neves, A.R. et al. Overexpression of ATP-activated P2X7 receptors in the intestinal mucosa is implicated in the pathogenesis of Crohn's disease. Inflamm. Bowel Dis. 20, 444-457 (2014).
253. Hofman, P. et al. Genetic and pharmacological inactivation of the purinergic P2RX7 receptor dampens inflammation but increases tumor incidence in a mouse model of colitis-associated cancer. Cancer Res 75, 1-11 (2015).
254. Marques, C.C. et al. Prophylactic systemic P2X7 receptor blockade prevents experimental colitis. Biochim. Biophys. Acta 1842, 65-78 (2014).
255. Kurashima, Y. et al. Extracellular ATP mediates mast cell-dependent intestinal inflammation through P2X7 purinoceptors. Nat. Commun. 3, 1034 (2012).
256. Broere, F., van der Zee, R. & van Eden, W. Heat shock proteins are no DAMPs, rather 'DAMPERs'. Nat. Rev. Immunol. 11, 565-565 (2011).
257. Chen, G.Y. & Nunẽz, G. Are heat shock proteins DAMPs? Nat. Rev. Immunol. 11, 565-565 (2011).